tetano
Editor, Senior Moderator
Clin Microbiol Infect
. 2025 Oct 13:S1198-743X(25)00474-4.
doi: 10.1016/j.cmi.2025.09.023. Online ahead of print. Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies
Sergey Yegorov[SUP] 1 [/SUP], Om D Patel[SUP] 1 [/SUP], Harsh Sharma[SUP] 1 [/SUP], Taha Khan[SUP] 1 [/SUP], Ribhav Gupta[SUP] 1 [/SUP], Michael Yao[SUP] 1 [/SUP], Ashwin Sritharan[SUP] 2 [/SUP], Noam Silverman[SUP] 1 [/SUP], Eleanor Pullenayegum[SUP] 3 [/SUP], Matthew S Miller[SUP] 4 [/SUP], Mark Loeb[SUP] 5 [/SUP]
Affiliations
Background: Seasonal influenza vaccination may be effective against severe influenza disease.
Objectives: To assess evidence on the real-world effectiveness of influenza vaccination in preventing severe influenza-related outcomes.
Data sources: PubMed, Ovid, and Cochrane CENTRAL from inception to September 24, 2024.
Study eligibility criteria: Observational test-negative design studies reporting influenza vaccine effectiveness (IVE) against influenza-associated hospitalisation, death, pneumonia, intensive care unit (ICU) admission, or ventilatory support (VS).
Participants: Hospitalized adults and children with laboratory-confirmed influenza and inpatient controls who tested negative for influenza infection.
Interventions: Influenza vaccination.
Assessment of risk of bias: Newcastle-Ottawa Scale (NOS) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) were used to assess study quality and evidence certainty.
Methods of data synthesis: We extracted study characteristics and odds ratio (OR) or IVE estimates and corresponding 95% confidence intervals (95% CI). Both crude and adjusted estimates were considered and analysed using a random-effects model. We calculated pooled IVE overall and by season, age group, circulating strains, vaccine type and match between vaccine and circulating strains.
Results: Overall, 7727 publications were identified, 461 reviewed, 165 included. Pooled IVE was 42% (95% CI 39-44) against influenza-associated hospitalisation (very low certainty), 36% (95% CI 24-46) against death (no certainty), 51% (95% CI 36-63) against pneumonia (low certainty), 52% (95% CI 38-63) against ICU admission (very low certainty), and 55% (95% CI 44-64) against VS (low certainty). IVE varied by age and was generally higher (up to 2-fold) in children compared to adults. Higher IVE was observed against influenza A(H1N1) compared to A(H3N2) and in seasons with good vaccine match. Hospitalisation IVE was slightly higher for quadrivalent (45% (95% CI, 32-56) compared to trivalent (36% (95% CI, 27-43) vaccine.
Conclusions: Seasonal influenza vaccination moderately reduces severe influenza-related outcomes, particularly in children, against A(H1N1), and with good vaccine-strain match.
Prospero registration: CRD42023476003.
. 2025 Oct 13:S1198-743X(25)00474-4.
doi: 10.1016/j.cmi.2025.09.023. Online ahead of print. Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies
Sergey Yegorov[SUP] 1 [/SUP], Om D Patel[SUP] 1 [/SUP], Harsh Sharma[SUP] 1 [/SUP], Taha Khan[SUP] 1 [/SUP], Ribhav Gupta[SUP] 1 [/SUP], Michael Yao[SUP] 1 [/SUP], Ashwin Sritharan[SUP] 2 [/SUP], Noam Silverman[SUP] 1 [/SUP], Eleanor Pullenayegum[SUP] 3 [/SUP], Matthew S Miller[SUP] 4 [/SUP], Mark Loeb[SUP] 5 [/SUP]
Affiliations
- PMID: 41093140
- DOI: 10.1016/j.cmi.2025.09.023
Background: Seasonal influenza vaccination may be effective against severe influenza disease.
Objectives: To assess evidence on the real-world effectiveness of influenza vaccination in preventing severe influenza-related outcomes.
Data sources: PubMed, Ovid, and Cochrane CENTRAL from inception to September 24, 2024.
Study eligibility criteria: Observational test-negative design studies reporting influenza vaccine effectiveness (IVE) against influenza-associated hospitalisation, death, pneumonia, intensive care unit (ICU) admission, or ventilatory support (VS).
Participants: Hospitalized adults and children with laboratory-confirmed influenza and inpatient controls who tested negative for influenza infection.
Interventions: Influenza vaccination.
Assessment of risk of bias: Newcastle-Ottawa Scale (NOS) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) were used to assess study quality and evidence certainty.
Methods of data synthesis: We extracted study characteristics and odds ratio (OR) or IVE estimates and corresponding 95% confidence intervals (95% CI). Both crude and adjusted estimates were considered and analysed using a random-effects model. We calculated pooled IVE overall and by season, age group, circulating strains, vaccine type and match between vaccine and circulating strains.
Results: Overall, 7727 publications were identified, 461 reviewed, 165 included. Pooled IVE was 42% (95% CI 39-44) against influenza-associated hospitalisation (very low certainty), 36% (95% CI 24-46) against death (no certainty), 51% (95% CI 36-63) against pneumonia (low certainty), 52% (95% CI 38-63) against ICU admission (very low certainty), and 55% (95% CI 44-64) against VS (low certainty). IVE varied by age and was generally higher (up to 2-fold) in children compared to adults. Higher IVE was observed against influenza A(H1N1) compared to A(H3N2) and in seasons with good vaccine match. Hospitalisation IVE was slightly higher for quadrivalent (45% (95% CI, 32-56) compared to trivalent (36% (95% CI, 27-43) vaccine.
Conclusions: Seasonal influenza vaccination moderately reduces severe influenza-related outcomes, particularly in children, against A(H1N1), and with good vaccine-strain match.
Prospero registration: CRD42023476003.